Goldman Sachs, AllianceBernstein, ClearBridge Investments, and Deloitte to co-host a series of investor launch events for the 2022 Access to Medicine Index

The Access to Medicine Index ranks 20 of the world’s largest pharma companies on how they manage material risks and opportunities related to access to medicine, including value drivers such as governance, compliance, R&D, pricing, management of intellectual property and product delivery. 

Three events, three timezones 

To mark the launch of the 2022 Access to Medicine Index, the three in-person events aim to provide institutional investors with the opportunity to dive into the findings of the new report, attend panel discussions on global health and investment trends and participate in meetings with pharmaceutical companies to discuss past performance and future plans. 

The three events each focus on companies from a specific geographic region and will be co-hosted by Goldman Sachs, AllianceBernstein and ClearBridge Investments, and Deloitte respectively.   

SPEAKERS INCLUDE  

• Geetha Tharmaratnam, Chief Impact Investment Officer, WHO Foundation

• Keyur Parekh, Managing Director, Healthcare Team, Goldman Sachs  

• Suerie Moon, Co-Director, Global Health Centre and Professor of Practice, Interdisciplinary Programmes and International Relations/Political Science, Geneva Graduate Institute 

• Rob Yates, Director, Global Health Programme; Executive Director, Centre for Universal Health, Chatham House 

• Jay Iyer, CEO, Access to Medicine Foundation 

PANELISTS INCLUDE

• Dana Bruce, Director of Development & Strategic Partnerships, U.S. Global Leadership Coalition  

• Julie Garfieldt Kofoed, Senior Director for Sustainable Development Initiatives, United Nations Foundation  

• Meg Jones-Monteiro, Senior Program Director – Health Equity, ICCR 

SPEAKERS INCLUDE  

• Hayato Urabe, Senior Director, Investment Strategy, Portfolio Development and Innovations, Global Health Innovative Technology (GHIT) Fund

• Shiina Ishige, Public Relations department, AfriMedico

• Shinichi Kohguchi, Senior Stewardship Officer, Sumitomo Mitsui Trust Asset Management Co. LTD.

• Shuhei Nomura, Associate Professor, Health Policy and Management, Keio University School of Medicine; Assistant Professor of Global Health Policy, University of Tokyo Graduate School of Medicine

Additional information 

To attend, or for more information about the 2022 launch events, please contact Mara Lilley, Investor Engagement Manager, at the Access to Medicine Foundation.

Learn more about how we work with investors

Read more

2022 Access to Medicine Index 

The 2022 Access to Medicine Index report marks the eighth edition of the Access to Medicine Index, which was first published in 2008. It evaluates and compares 20 of the world’s leading research-based pharmaceutical companies according to their efforts to improve access to medicine in low- and middle-income countries (LMICs). 

The latest Index was published on 15 November 2022 and includes a total of 31 metrics covering the core role for pharmaceutical companies on access to medicine in strategy, compliance, R&D, pricing and product delivery. Data analysed relates to 83 diseases, conditions and pathogens that disproportionately impact people living in the 108 LMICs in scope of the Index where better access to medicine is most urgently needed. 

The Access to Medicine Foundation is an independent non-profit organisation that seeks to transform the healthcare ecosystem by motivating and mobilising companies to expand access to their essential healthcare products in LMICs.  

How investors use the Access to Medicine Index   

The Access to Medicine Index is viewed by asset managers, asset owners and analysts as one of the most credible sources of information for assessing how pharmaceutical companies strengthen their licence to operate globally and expand in international markets. 134 investors – together managing assets of more than USD 21 trillion – have endorsed the Index by signing the Access to Medicine Index Investor Statement, committing to using the Index in their investment analysis and engagements with companies, and gaining direct access to our analysts and resources.